Pharmaceuticals News & Analysis

Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What’s next for the stock? We take a look at earnings estimates for some clues.

Investors need to pay close attention to Agios (AGIO) stock based on the movements in the options market lately.

An age-old battle in pharmaceuticals could further rattle Eli Lilly stock and its potential $100 billion market in weight-loss drugs.
The post The Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion Market appeared first on Investor&#039…

Alnylam (ALNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.

Vertex (VRTX) reported earnings 30 days ago. What’s next for the stock? We take a look at earnings estimates for some clues.

The consensus price target hints at a 27% upside potential for Tarsus Pharmaceuticals (TARS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock’s prospects.

Whether you’re a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock’s prospects.

Investors need to pay close attention to ACADIA Pharmaceuticals (ACAD) stock based on the movements in the options market lately.

Terns Pharmaceuticals Inc.’s stock jumped 7.5% premarket Tuesday, after the company announced positive data from an early-stage trial of a treatment for chronic myeloid leukemia.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

This is the first of a few generic drug launches planned for December https://finance.yahoo.com/news/elite-pharmaceuticals-announces-commercial-launch-110000126.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cucmVkZGl0LmNvbS8&guce_referrer_sig=A…

GILD vs. VRTX: Which Stock Is the Better Value Option?

MIRM’s lead drug, Livmarli, is driving revenues and the momentum is likely to continue. The company’s efforts to build its pipeline beyond Livmarli also hold promise.

The consensus price target hints at a 44.4% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Acurx Pharmaceuticals (ACXP) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock’s potential for a turnaround in the near term.

Ionis Pharmaceuticals (IONS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

NRx Pharmaceuticals (NRXP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.

Sarepta in-licenses rights to four clinical-stage and three preclinical-stage programs targeting muscle, central nervous system and rare pulmonary disorders.

Acadia signs a $610 million exclusive global license agreement with Saniona to develop and commercialize SAN711 for neurological disorder indications.

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Sonoma Pharmaceuticals (SNOA) could be a great choice. It is one of the several stocks that passed through our ‘Fast-Paced Momentum at a Bargain’ screen.

The consensus price target hints at a 31.3% upside potential for ANI (ANIP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Here is how Agios Pharmaceuticals (AGIO) and Twist Bioscience (TWST) have performed compared to their sector so far this year.

ALNY reports submitting an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.

Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta Therapeutics.
The post Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal appeared first on Investor's Busin…

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock’s prospects.

Costco, T-Mobile US, Uber Technologies, SandRidge and Elite Pharmaceuticals are included in this Analyst Blog.

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -17.24% and 20.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Adial Pharmaceuticals (ADIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.

Investors need to pay close attention to Regeneron (REGN) stock based on the movements in the options market lately.

Is it a good or bad thing when a stock experiences a golden cross technical event?

Here is how Atea Pharmaceuticals, Inc. (AVIR) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.

The Oracle of Omaha has been accumulating billions of dollars in the past few years… and you can bet that there’s a reason. Tracey Ryniec looks to history to uncover the meaning behind Mr. Buffett’s recent selling and how it can generate huge returns for patient value investors.

Following the FDA’s approval, Jazz’s Ziihera becomes the first dual HER2-targeted bispecific antibody and chemotherapy-free treatment approved for biliary tract cancer.

PFE vs. NVO: Which Stock Is the Better Value Option?

The availability of the FDA-approved drug via McKesson’s cell and gene therapies business is expected to give patients improved treatment options for SCD.

Function: Larger Degree Trend Higher (Intermediate Degree orange).

ANI (ANIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The board of Acurx Pharmaceuticals has approved the purchase of up to $1 million in bitcoin to hold as a treasury reserve asset.

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.